Tiotropium bromide: An update

Open Respiratory Medicine Journal

Volumn 3, Issue , 2009, Pages 43-52

  Heredia, Josep Lluis ^a  

^a HOSPITAL MÚTUA DE TERRASSA   (Spain)

Author keywords

COPD; COPD exacerbations; COPD mortality; Lung function; Quality of life; Tiotropium bromide

Indexed keywords

FLUTICASONE PROPIONATE; FORMOTEROL; IPRATROPIUM BROMIDE; PLACEBO; SALBUTAMOL; SALMETEROL; TIOTROPIUM BROMIDE;

ABDOMINAL PAIN; BRONCHODILATATION; BRONCHODILATING ACTIVITY; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DISEASE EXACERBATION; DRUG RECEPTOR BINDING; DYSPEPSIA; DYSPHAGIA; DYSPNEA; HEALTH STATUS; HEART ARREST; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERINFLATION; INSPIRATORY CAPACITY; LUNG FUNCTION; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; REVIEW; SPIROMETRY; SYSTEMATIC REVIEW; TACHYCARDIA; TACHYPHYLAXIS; URINE RETENTION; XEROSTOMIA;

EID: 70350055703     PISSN: None     EISSN: 18743064     Source Type: Journal    
DOI: 10.2174/1874306400903010043     Document Type: Review

References (67)

1. Barnes PJ. Muscarinic receptor subtypes in airways. Life Sci. 1993; 52: 521-7.
2. Mak JC, Barnes PJ. Autoradiographic visualization of muscarinic receptor subtypes in human and guinea pig lung. Am Rev Respir Dis 1990; 141: 1559-68.
3. Eglen RM, Hegde SS, Watson N. Muscarinic receptor subtypes and smooth muscle function. Pharmacol Rev 1996; 48: 531-65.
4. Patel HJ, Barnes PJ, Tadjkarimi S, Yacoub MH, Belvisi MG. Evidence for prejunctional muscarinic autoreceptors in human and guinea pig trachea. Am J Respir Crit Care Med 1995; 152: 872-8.
5. Roffel AF, Elzinga CR, Zaagsma J. Muscarinic M3 receptors mediate contraction of human central and peripheral airway smooth muscle. Pulm Pharmacol 1990; 3: 47-51.
6. Ramnarine SL, Haddad EB, Khawaja AM, Mak JC, Rogers DF. On muscarinic control of neurogenic mucus secretion in ferret trachea. J Physiol 1996; 494: 577-86.
7. Disse B, Speck GA, Rominger KL, Witek TJ, Jr, Hammer R. Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci 1999; 64: 457-64.
8. Haddad EB, Mak JC, Barnes PJ. Characterization of {3H} 3Ba 679 BR, a slowly dissociating muscarinic antagonist, in human lung: radioligand binding and autoradiographic mapping. Mol Pharmacol 1994; 45: 899-907.
9. Maessens FPV, Smeets JJ, Sledsens TJH, et al. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease. Eur Respir J 1995; 8: 1506-13.
10. Disse B, Reichl R, Speck G, Traunecker W, Ludwig Rominger KL. Life Sci 1993; 52: 537-544.
11. Calverly PM, Lee A, Towse L, et al. Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease. Thorax 2003; 58: 855-60.
12. Tashkin D, Kesten S. Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses. Chest 2003; 123: 1441-9.
13. Powrie DJ, Wilkinson TM, Donaldson GC, et al. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. Eur Respir J 2007; 30: 472-8.
14. Pieper MP, Chaudhary NI, Park JE. Acetylcholine-induced proliferation of fibroblast and myofibroblast in vitro is inhibited by tiotropium bromide. Life Sci 2007; 30: 2270-3.
15. Barnes P. New developments in anticholinergic drugs. Eur Respir Rev 1996; 6: 290-4.
16. Gross NJA, Skorodins MS. Cholinergic bronchomotor tone in COPD: estimates of its amount in comparison to normal. Chest 1989; 96: 984-7.
17. nd ed. London: Science Press 2002.
18. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Guidelines: workshop report. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Updated Setember, 2005. [Date last accessed: January 13, 2007]. Available from: http: //www.goldcop.com/ GuidelineList.asp?!1=2&!=1
19. Rodríguez-Carballeira M, Heredia JL, Rué M, Quintana S, Gómez L. The bronchodilator test with increasing doses of terbutaline in chonic obstructive pulmonary disease patients. Pulm Pharmacol Ther 2001; 14: 61-5.
20. Rodríguez-Carballeira M, Heredia JL, Gómez L, Quintana S, Viñas C. Contribution of ipratropium bromide to the bronchodilator test in patients with chronic obstructive pulmonary disease. Pulm Pharmacol Ther 1999; 12: 43-8.
21. Rodríguez-Carballeira M, Heredia JL, Rué M, Quintana S, Almagro P. The bronchodilator test in chronic obstructive pulmonary disease: interpretation methods. Respir Med 2007: 101: 34-42.
22. Tashkin DP, Celli B, Decramer M., Liu D, Burkhart D, Cassino C. Bronchodilator responsiveness in patients with COPD. Eur Respir J. 2008; 31: 742-50.
23. Littner MR, Ilowite JS, Tashkin DP, et al. Long-acting bronchodilation with once-daily dosing of tiotropium (spiriva) in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161: 1136-42.
24. Van Noord JA, Smeets JJ, Custers FL, et al. Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease. Eur Respir J 2002; 19: 639-44.
25. Casaburi R, Mahler DA, Jones PW et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19: 217-24.
26. Vincken W, Van Noord JA, Greefhorst AP, et al. Dutch/Belgian Tiotropium Study Group. Improved health outcomes in patients with COPD during 1year treatment with tiotropium. Eur Respir J 2002; 19: 209-16.
27. Donohue JF, Van Noord JA, Bateman ED, et al. A 6-month, placebocontrolled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122: 47-55.
28. Brusasco V, Hodder R, Miravitlles M, et al. Health outcomes following treatment for six months with once daily tiotropium compared twice daily salmeterol in patients with COPD. Thorax 2003; 58: 399-404.
29. Tashkin DP, Celi B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543-54.
30. Cazzola M, Santus P, D'Adda A, Pizzolato S, Di Marco F. Acute effects of higher than standard doses of salbutamol and ipratropium on tiotropium-induced bronchodilation in patients with stable COPD. Pulm Pharmacol Ther 2008. Web/URL PM: 19038356.
31. van Noord JA, Aumann Jl, Janssens E, et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006; 129: 509-17.
32. Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease. Annals Int Med 2007; 146: 545-56.
33. Taube C, Lehnigk B, Paasch K, et al. Factor analysis of changes in dyspnea and lung function parameters after bronchodilation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 162: 216-20.
34. O'Donell DE, Lam M, Webb KA. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: 542-9.
35. Marin JM, Carrizo SJ, Gascon M, et al. Inspiratory capacity, dynamic hyperinflation, breathlessness, and exercise performance during the 6-minute-walk test in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 63: 1395-9.
36. Celli B, Zu Wallack R, Wang S, et al. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 2003; 24: 1743-8.
37. O'Donnell DE, Flüge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnea and exercise tolerance in COPD. Eur Respir J 2004; 23: 832-40.
38. Gelb AF, Taylor CF, Cassino C, Shinar CM, Schein MJ, Zamel N. Pulm Pharmacol Ther 2009. Web/URL. PM: 19138754.
39. Mahler DA, Weinberg DH, Wells CK, et al. The measurement of dyspnea: contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984; 85: 751-8.
40. British Thoracic Society Standards of Care Subcommittee on pulmonary Rehabilitation. Pulmonary Rehabilitation. Thorax 2001; 56: 827-34.
41. American Thoracic Society. Pulmonary rehabilitation - 1999: official statement of the American Thoracic Society. Am J Respir Crit Care Med 1999; 159: 1666-82.
42. Casaburi R, Kukafka D, Cooper CB, Witek TJ, Jr, Kesten S. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 2005; 127: 809-17.
43. Almago P, Calbo E, Ochoa de Echagüen A, Barreiro B, Quintana S, Heredia JL. Mortality after hospitalization for COPD. Chest 2002; 121: 1441-8.
44. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196-204.
45. Wedzicha JA, Calverly MA, Seemungal TA, Hagan G, Ansari Z, Stockley RA. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/ fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008; 177: 19-26.
46. Rodrigo GJ, Nannini LJ. Tiotropium for the treatment of stable chronic obstructive pulmonary disease: a systematic review with meta-analysis. Pulm Pharmacol Ther 2007; 20: 495-502.
47. Barr RG, Bourbeau J, Camargo CA, Ram FS. Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. Thorax 2006; 61: 854-62.
48. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE. The effects of a smoking cessation intervention on 14.5 year mortality: a randomized clinical trial. Ann Intern Med 2005; 142: 233-239.
49. Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008; 178: 332-8.
50. Suissa S. Methodologic shortcomings of the INSPIRE randomized trial. Am J Respir Crit Care Med 2008: 178: 543-4.
51. van der Valk P, Monninkhof E, van der Palen J, Zielhuis G, van Herwaarden C. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am J Respir Crit Care Med 2002; 166: 1358-63.
52. Gershon AS, Wang L, To T, Luo J, Upshur RE. Survival with tiotropium compared to long-acting beta2-agonist in chronic obstructive pulmonary disease. COPD 2008; 5: 229-34.
53. Anthonissen NR, Connet JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhales anticholinergic bronchodilator on the rate of decline of FEV1: the Lung Health Study. JAMA 1994; 272: 1497-1505.
54. Anzueto A, Tashkin D, Menjoge S. One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium. Pulm Pharmacol Ther 2005; 18: 75-81.
55. The Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000; 343: 1902-9.
56. Paweles RA, Löfdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med 1999; 340: 1948-53.
57. Burge PS, Calverly PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: 1297-303.
58. Decramer M, Rutten-van Mölken M, Dekhuijzen PN, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomized placebo-controlled trial. Lancet 2005; 365: 1552-60. (Erratum, Lancet 2005; 366: 984).
59. Kesten S, Jara M, Wentworth C, Lanes S. Pooled clinical trial analysis of tiotropium safety. Chest 2006; 130: 1695- 1703.
60. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008; 300: 1439-50.
61. Anthonisen MNR, Connett JE, Enright PF, et al. Hospitalization and mortality in the lung heath study. Am J Respir Crit Care Med 2002; 166: 333-339.
62. de Luise C, Lanes SF, Jacobsen J, Pedersen L, Sorensen HT. Cardiovascular an respiratory hospitalizations and mortality among users of tiotropium in Denmark. Eur J Epidemiol 2007; 22: 267-72.
63. O'Connor BJ, Towse LJ, Barnes PJ. Prolonged effect of tiotropium bromide on metacholine-induced bronchoconstriction in asthma. Am J Respir Crit Care Med 1996; 154: 876-80.
64. Fardon T, Haggart K, Lee DK, Lipworth BJ. A proof of concept study to evaluate stepping down the dose of fluticasone in combination with salmeterol and tiotropium in severe persistent asthma. Respir Med 2007; 101: 1218-28.
65. Kanazawa H. Anticholinergic agents in asthma: chronic bronchodilator therapy, relief of acute severe asthma, reduction of chronic viral inflammation and prevention of airway remodeling. Curr Opin Pulm Med 2006; 12: 60-7.
66. Magnussen H, Bugnas B, van Noord J, Schmidt P, Gerken F, Kesten S. Improvements with tiotropium in COPD patients with concomitant asthma. Respir Med 2008; 102: 50-6.
67. Iwamoto H, Yokoyama A, Shiota N, et al. Tiotropium bromide is effective for severe asthma with noneosinophilic phenotype. Eur Respir J 2008; 31: 1379-82.